Despite the progress in outcomes seen with immunotherapy in various malignancies, including nonsmall cell lung cancer, the benefits are less in small cell lung cancer, malignant pleural mesothelioma and thymic… Click to show full abstract
Despite the progress in outcomes seen with immunotherapy in various malignancies, including nonsmall cell lung cancer, the benefits are less in small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours. New effective treatment options are needed, guided via more in-depth insights into the pathophysiology of these rare malignancies. This review comprehensively presents an overview of the clinical presentation, diagnostic tools, staging systems, pathophysiology and treatment options for these rare thoracic cancers. In addition, opportunities for further improvement of therapies are discussed. SCLC, mesothelioma and thymoma are rare thoracic cancers. Diagnosis and treatment options should therefore be discussed in a multidisciplinary discussion. Although progress has been made with the entrance of ICI, novel strategies are being studied. https://bit.ly/3TTUgY9
               
Click one of the above tabs to view related content.